|Title:||Medical use for tachykinin antagonists|
|Abstract:||The present invention relates to the use of tachykinin antagonists, including substance P antagonists and other neurokinin antagonists, in the treatment of emesis. Also described are novel tachykinin antagonists of formula (I), processes for their preparation, pharmaceutical compositions containing them and their medical use. ##STR00001## wherein R represents the ring A ##STR00002## or 2-pyridinyl or 2-pyridinyl-N-oxide; R.sup.1 is selected from halogen atoms and C.sub.1-4alkyl, C.sub.1-4alkoxy, trifluoromethyl, and S(O).sub.nC.sub.1-4alkyl groups; R.sup.2 and R.sup.3, which may be the same or different, each independently are selected from hydrogen and halogen atoms and C.sub.1-4alkyl, C.sub.1-4alkoxy, trifluoromethyl and cyano groups; n represents zero, 1 or 2; and pharmaceutically acceptable salts and solvates thereof.|
|Inventor(s):||Hagan; Russell Michael (Ware, GB), Bunce; Keith Thomas (Ware, GB)|
|Assignee:||Glaxo Group Limited (Middlesex, GB)|
Patent Claim Types:|
see list of patent claims
Back Citations: 54th percentile
Forward Citations: 0th percentile
|Patent Number||Expiration Date|
|7,214,692||May 08, 2015|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|European Patent Office||1082959||► subscribe|
|European Patent Office||0919245||► subscribe|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.